Replimune Group (NASDAQ:REPL) Hits New 52-Week High on Analyst Upgrade

Shares of Replimune Group, Inc. (NASDAQ:REPL) reached a new 52-week high during trading on Friday after BMO Capital Markets raised their price target on the stock from $14.00 to $18.00. BMO Capital Markets currently has an outperform rating on the stock. Replimune Group traded as high as $15.46 and last traded at $15.34, with a volume of 794946 shares trading hands. The stock had previously closed at $11.05.

Several other equities research analysts have also weighed in on the company. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. JPMorgan Chase & Co. increased their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm initiated coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research note on Friday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and a consensus price target of $17.00.

Insider Transactions at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of the business. Baker BROS. Advisors LP grew its holdings in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Replimune Group by 12.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Millennium Management LLC lifted its position in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after purchasing an additional 2,656,173 shares during the period. Braidwell LP lifted its position in Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after buying an additional 32,555 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Price Performance

The stock has a market cap of $1.02 billion, a P/E ratio of -4.90 and a beta of 1.19. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The company’s fifty day simple moving average is $11.59 and its 200-day simple moving average is $9.72.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, sell-side analysts forecast that Replimune Group, Inc. will post -3.02 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.